Final overall survival (OS) analysis of first-line (1L) FOLFOX-4 ± cetuximab (cet) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial.

3521Background: The survival advantage conferred by the addition of cet to FOLFOX chemotherapy was verified in TAILOR, the first prospective, randomized, phase 3 study of the addition of cet to 1L ...